GeneOne Life Science KRX:011000KOSPI
진원생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, GeneOne Life Science reported revenue of ₩2.1bn, down 69.8% year on year, and an operating loss of ₩12.8bn. GeneOne Life Science (진원생명과학) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
GeneOne Life Science quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.1bn | -69.8% | −₩12.8bn | −₩18.9bn |
| Q1 2026 | ₩2.6bn | -69.6% | −₩2.3bn | −₩2.4bn |
| Q4 2025 derived | ₩2.7bn | -74.8% | −₩13.1bn | −₩16.1bn |
| Q3 2025 | ₩5.1bn | -42.9% | −₩11.7bn | −₩11.5bn |
| Q2 2025 | ₩6.8bn | -26.7% | −₩10.2bn | −₩15.4bn |
| Q1 2025 | ₩8.5bn | +20.9% | −₩9.1bn | −₩8.8bn |
| Q4 2024 derived | ₩10.5bn | -17.6% | −₩9.9bn | −₩15.6bn |
| Q3 2024 | ₩8.9bn | -24.2% | −₩10.4bn | −₩10.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
GeneOne Life Science top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest GeneOne Life Science news Korean headlines
No articles yet.